694499-26-8

Basic information

• Product Name: 4-(4-Methylpiperazinomethyl)-3-(trifluoromethyl)aniline
• Synonyms: 4-(4-Methylpiperazinomethyl)-3-(trifluoromethyl)aniline;4-((4-Methylpiperazin-1-yl)methyl)-3-trifluoromethylphenylamine;4-(4-Methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline;4-[(4-Methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)benzenamine;BenzenaMine, 4-[(4-Methyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)-;4-[(4-Methyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)aniline;4-[(4-Methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline 95+%;5-Amino-2-[(4-methylpiperazin-1-yl)methyl]benzotrifluoride, 1-[4-Amino-2-(trifluoromethyl)benzyl]-4-methylpiperazine
• CAS NO: 694499-26-8
• Molecular Formula: C₁₃H₁₈F₃N₃
• Molecular Weight: 273
• Mol File: 694499-26-8.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 329.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.227
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.55±0.10(Predicted)
• CAS DataBase Reference: 4-(4-Methylpiperazinomethyl)-3-(trifluoromethyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methylpiperazinomethyl)-3-(trifluoromethyl)aniline(694499-26-8)
• EPA Substance Registry System: 4-(4-Methylpiperazinomethyl)-3-(trifluoromethyl)aniline(694499-26-8)

Safety Data

• Hazardous Substances Data: 694499-26-8(Hazardous Substances Data)

Usage

Uses

4-(6-Acryloyloxyhexyloxy)-benzoesure (4-cyanophenylester) can be used as an intermediate in organic synthesis, mainly used in laboratory research and development and in the process of chemical and pharmaceutical synthesis.

Synthesis

4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline Into a solution 4-methyl-1-(4-nitro-2-(trifluoromethyl)benzyl)piperazine (1.5 g, 5 mmol) in MeOH (250 mL) was added Raney Nickel (0.15 g, 10 wt %). The suspension was stirred under hydrogen atmosphere (50 psi) for 24 hrs and monitored by TLC. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to yield the desired product (1.36 g, 100%). 1H NMR (300 MHz, CDCl3) δ: 7.43-7.46 (1H, d, J=9.0 Hz), 6.91 (1H, s), 6.77-6.80 (1H, d J=9.0 Hz), 3.77 (2H, s), 3.54 (2H, s), 2.53 (8H, brs), 2.34 (3H, s).

Upstream product

• 109-01-3 1-methyl-piperazine 
• 433-97-6 2-trifluoromethylbenzoic acid 
• 98187-15-6 3-trifluoromethyl-4-nitrobenzoyl chloride 
• 393-06-6 4-amino-2-(trifluoromethyl)benzoic acid 
• 876322-73-5 4-amino-2-(trifluoromethyl)benzaldehyde 
• 859027-06-8 (4-nitro-2-(trifluoromethyl)phenyl)methanol 
• 350-96-9 2,2,2-trifluoro-N-(4-methylphenyl)acetamide 
• 853297-03-7 (4-methylpiperazin-1-yl)-[4-nitro-2-(trifluoromethyl)phenyl]methanone 
• 50551-17-2 4-nitro-2-(trifluoromethyl)benzaldehyde 
• 630125-84-7 N-(4-bromomethyl-3-trifluoromethylphenyl)-2,2,2-trifluoroacetamide 
• 65934-74-9 3-(trifluoromethyl)-4-methylaniline 
• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 694499-22-4 1-(bromomethyl)-4-nitro-2-(trifluoromethyl) benzene 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 

Downstream Products

• 709045-31-8 N-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-2-nitro-benzamide 
• 853297-02-6 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea 
• 1265527-06-7 C₂₆H₂₆ClF₃N₆O₂ 
• 1421227-53-3 N-(6-(4-(2-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)amino)-2-oxoethyl)phenoxy)pyrimidin-4-yl)cyclopropanecarboxamide 
• 1421227-52-2 N-(6-(4-(3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) ureido) phenoxy)pyrimidin-4-yl)cyclopropanecarboxamide 
• 1428445-61-7 1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea 
• 853299-07-7 1-[4-(2-aminopyrimidine-4-yloxy)phenyl]-3-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]urea 
• 1613168-64-1 N-(5-(3-fluoro-4-((2-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)amino)-2-oxoethyl)amino)phenyl)pyridin-2-yl)cyclopropanecarboxamide 

Relevant articles and documents

Insights into the modular design of kinase inhibitors and application to Abl and Axl

Scaffold hopping is a common strategy for generating kinase inhibitors that bind to the DFG-out inactive conformation. Small structural differences in inhibitor scaffolds can have significant effects on potency and selectivity across the kinome, however, these effects are often not studied in detail. Herein, we outline a design strategy to generate an array of DFG-out conformation inhibitors with three different hinge-binders and two DFG-pocket groups. We studied inhibitor selectivity across a large segment of the kinome and elucidated binding preferences that can be used in scaffold hopping campaigns. Using these analyses, we identified two selective inhibitors that display low nanomolar potency against Axl or wild-type and clinically relevant mutants of Abl.

Alkynyl pyrimidine or alkynyl pyridine compound as well as composition and application thereof

The invention relates to alkynyl pyrimidine or alkynyl pyridine compounds represented by a formula (I) or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof. The invention also discloses a pharmaceutical composition contain

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a